Compare KEN & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEN | SUPN |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | N/A | 2012 |
| Metric | KEN | SUPN |
|---|---|---|
| Price | $61.03 | $47.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $63.25 |
| AVG Volume (30 Days) | 10.2K | ★ 664.8K |
| Earning Date | 12-03-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.83% | N/A |
| EPS Growth | ★ 177.70 | N/A |
| EPS | ★ 8.96 | N/A |
| Revenue | ★ $803,304,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | N/A | $23.36 |
| P/E Ratio | $6.50 | ★ N/A |
| Revenue Growth | ★ 8.15 | 4.54 |
| 52 Week Low | $27.10 | $29.16 |
| 52 Week High | $62.88 | $57.65 |
| Indicator | KEN | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 54.30 |
| Support Level | $59.90 | $45.36 |
| Resistance Level | $62.68 | $47.26 |
| Average True Range (ATR) | 1.10 | 1.23 |
| MACD | -0.27 | 0.40 |
| Stochastic Oscillator | 60.27 | 91.64 |
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.